Brief: Geron Announces FDA Approval Of Rytelo For Treatment Of Adult Patients With Lower-Risk Mds With Transfusion-Dependent Anemia

Geron

07/06/2024 03:00

June 6 (Reuters) - Geron Corp  GERN.O :
    * GERON ANNOUNCES FDA APPROVAL OF RYTELO™ (IMETELSTAT), A
FIRST-IN-CLASS TELOMERASE INHIBITOR, FOR THE TREATMENT OF ADULT
PATIENTS WITH LOWER-RISK MDS WITH TRANSFUSION-DEPENDENT ANEMIA
    * GERON - FDA APPROVAL OF RYTELO IS BASED RESULTS FROM
IMERGE
PHASE 3 CLINICAL TRIAL, IMERGE TRIAL MET ITS PRIMARY & KEY
SECONDARY ENDPOINTS,

Source text for Eikon:  ID:nBw4wdP1Ha 
Further company coverage:  GERN.O 

 ((Reuters.Briefs@thomsonreuters.com;))